TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01768572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous placebo
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous placebo
Description: Pharmaceutical form: solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous placebo
Description: Pharmaceutical form: solution Route of administration: intravenous
Study: NCT03503604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
Study: NCT00685113

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal ring inserted vaginally and replaced every 4 weeks
Study: NCT02321553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice
Description: brown rice cake
Study: NCT03503604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
Study: NCT04082494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music via internet and noise canceling headphones
Description: Optional music via internet and noise canceling headphones will be offered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverages
Description: Beverages will be optionally offered (with and without sugar, warm or cold).
Study: NCT02259777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine
Description: Fixed dose combination tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat, high caloric meal
Study: NCT03503604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV infusion, 400 mg/m2 every 2 weeks
Study: NCT05982756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAG pre-excitation regimen with Bortezomib
Description: Bortezomib+DAG pre-excitation regimen: Bortezomib (specification 3.5mg, intravenous injection, 4 times a course of treatment, 1.3mg/m2, d1, 4, 8, 11; doxorubicin liposome injection 5 mg/ m2, intravenous infusion, once every other day, 5 times in total; cytarabine 10 mg/m2 every 12 hours, subcutaneous injection, d1-14; G-CSF 200 μg/m2 daily, subcutaneous injection, d1-14 Days, WBC \>10×109/L during chemotherapy, postpone the use until it falls below this value;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAG pre-excitation regimen with Bortezomib
Description: Bortezomib+DAG pre-excitation regimen: Bortezomib (specification 3.5mg, intravenous injection, 4 times a course of treatment, 1.3mg/m2, d1, 4, 8, 11; doxorubicin liposome injection 5 mg/ m2, intravenous infusion, once every other day, 5 times in total; cytarabine 10 mg/m2 every 12 hours, subcutaneous injection, d1-14; G-CSF 200 μg/m2 daily, subcutaneous injection, d1-14 Days, WBC \>10×109/L during chemotherapy, postpone the use until it falls below this value;
Study: NCT00233142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Writing as therapeutic intervention

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral writing
Description: Non-expressive writing
Study: NCT00080119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Antibiotic for the prevention and treatment of TB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Antibiotic for the prevention and treatment of TB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole (TMP/SMX)
Description: Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole (TMP/SMX)
Description: Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoniazid Placebo (PL)
Description: Isoniazid placebo and TMP/SMX

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoniazid Placebo (PL)
Description: Isoniazid placebo and TMP/SMX
Study: NCT01195402

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary outpatient rehabilitation
Description: Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
Study: NCT00552656

Intervention type: DEVICE
Intervention: Firebird(TM) Sirolimus-Eluting Stent
Description: balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
Study: NCT01211210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil, oxaliplatin
Description: Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil, oxaliplatin
Description: Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
Study: NCT03733379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
Study: NCT02321553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice
Description: white rice cake
Study: NCT04239651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Delivered Cognitive Behavior Therapy (iCBT)
Description: Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
Study: NCT00319254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606 (Bosutinib)
Description: SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
Study: NCT02436538

Intervention type: OTHER
Intervention: Anti Mullerian hormone level; Mullerian duct anomaly type
Description: Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
Study: NCT01518842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal Bone Marrow Stem Cells
Description: One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
Study: NCT04561440

Intervention type: DIAGNOSTIC_TEST
Intervention: molecular karyotyping
Description: performed by NGS or CMA chip

Intervention type: DIAGNOSTIC_TEST
Intervention: molecular karyotyping
Description: performed by NGS or CMA chip
Study: NCT04573608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papacarie
Description: Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Description: The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
Study: NCT00555217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: 50 or 100mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan
Description: 50 or 100mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: 10, 20 or 40 mg/day
Study: NCT04131075

Intervention type: PROCEDURE
Intervention: Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)
Description: Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
Study: NCT03680183

Intervention type: DRUG
Intervention: Entecavir 1Mg Oral Tablet
Description: The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)

Intervention type: DRUG
Intervention: Entecavir 1Mg Oral Tablet
Description: The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
Study: NCT03920943

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of temperature using non-invasive means
Description: The study intervention will involve paramedics using the TAT device to measure temperature non-invasively,the first measurements made at least 5 minutes after insertion of the temperature probe (control measurement #1), and also prior to departure from the sending facility (control measurement #2). Once the patient is in the transport vehicle and the vehicle in motion for at least 10 minutes, the paramedics will measure the patient's temperature non-invasively using the TAT. If the transport time exceeds 1 hour, additional measurements taken at 1 hour intervals for the duration of transport (up to a total of 8 hours).
Study: NCT01142622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine nebulization
Description: Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine instillation
Description: Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
Study: NCT03733379

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole and Amoxicillin placebos
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole and Amoxicillin placebos
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
Study: NCT03094533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: total intravenous anesthesia with propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIMA
Description: volatile induction and maintenance anesthesia with sevoflurane
Study: NCT03770117

Intervention type: PROCEDURE
Intervention: Prehabilitation
Description: Participants who underwent Prehabilitation will have their CT scans analysed.

Intervention type: PROCEDURE
Intervention: Standard Procedure
Description: Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
Study: NCT04994548

Intervention type: PROCEDURE
Intervention: Endosocpic resection of early esophageal tumor
Description: under general anesthesia, by mucosectomy or endoscopic submucosal dissection
Study: NCT00005030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 66336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
Study: NCT02817243

Intervention type: DRUG
Group type: OTHER
Intervention: SP2086
Description: SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Description: SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
Study: NCT02717039

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
Study: NCT03733379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic placebo
Description: The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
Study: NCT00992459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buphenyl (NaPBA)
Description: Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
Study: NCT01511016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant leptin (metreleptin)
Description: Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
Study: NCT04046224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST-920
Description: Single dose of investigational product ST-920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST-920
Description: Single dose of investigational product ST-920
Study: NCT04759105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous BM-MSC
Description: intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: anaesthesia, no disc injection, no placebo injection
Study: NCT04520399

Intervention type: OTHER
Intervention: none intervention
Description: there is no intervention in this study

Intervention type: OTHER
Intervention: none intervention
Description: there is no intervention in this study
Study: NCT00794950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy.
Study: NCT03019094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The RENOVA tibial nerve stimulation system
Description: Study participants will be implanted with the RENOVA tibial nerve stimulation system
Study: NCT03413306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IST (ATG + CsA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IST (ATG + CsA)
Study: NCT01629277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop
Description: Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard insulin pump
Description: Subcutaneous insulin delivery will be administered according the standard insulin pump settings
Study: NCT02458833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Plate
Description: Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Plate
Description: Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
Study: NCT04161976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900027
Description: LY900027 administered to participants with T1DM using CSII.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Insulin lispro administered to participants with T1DM using CSII.